survodutide mastery course
Unit 2 of 12

Molecular Architecture

29 amino acids engineered for dual receptor activity and weekly dosing

Engineering a Dual Agonist

Survodutide starts from the 29-amino-acid glucagon backbone and introduces strategic modifications at key positions. These changes shift receptor selectivity, extend half-life through C18 fatty acid acylation, and produce a molecule capable of activating both GLP-1R and GCGR from a single weekly injection.

Interactive Structure Viewer

Explore the peptide backbone, modification sites, and acylation chemistry that define survodutide.

peptide structure viewer

key numbers

quick reference for survodutide's molecular design.

4,231 Da
molecular weight
29
amino acids (glucagon backbone)
>99%
albumin binding via C18 fatty diacid
~6 days
half-life (vs ~6 min for native glucagon)
Survodutide is an investigational peptide (BI 456906) developed by zealand pharma and boehringer ingelheim. It is not commercially available. All structural data described here come from preclinical characterization and published patent filings, not from a clinical pharmacopeia.

key terms

definitions for the structural concepts in this unit. tap to expand.

A Ac4c unnatural amino acid
1-aminocyclobutane-1-carboxylic acid. Replaces serine at position 2 to block DPP-4 cleavage. Its rigid cyclobutane ring creates a steric barrier that the enzyme cannot accommodate, extending the peptide's survival from minutes to days.
D DPP-4 enzyme
Dipeptidyl peptidase-4. A serine protease that cleaves native glucagon and GLP-1 between positions 2 and 3, destroying their biological activity within minutes. The Ac4c substitution at position 2 renders survodutide resistant to this enzyme.
C C18 fatty diacid modification
An 18-carbon fatty diacid (octadecanedioic acid) attached at lysine-24 via a GGSGSG-gammaE linker. It binds serum albumin non-covalently, creating a circulating depot that extends the half-life to ~6 days. The same acylation strategy is used by semaglutide and tirzepatide.
S SAR methodology
Structure-activity relationship. The systematic process of modifying individual amino acid positions and measuring the impact on receptor binding, selectivity, and pharmacokinetics. Zealand pharma used extensive SAR studies to identify the minimum set of modifications (positions 16, 18, 20, 23) needed for dual agonism.
A amidation modification
Conversion of the C-terminal carboxyl group to a carboxamide. This protects the peptide from carboxypeptidase degradation and is a standard stabilization technique for therapeutic peptides.

survodutide's structure -- the simple version

how scientists turned a natural hormone into a once-weekly drug that hits two targets.

Survodutide starts as a copy of glucagon, a natural 29-amino-acid hormone your pancreas makes to tell the liver to release stored energy. Scientists at Zealand Pharma then made four types of changes to this natural blueprint. First, they swapped one building block near the front of the chain (position 2) with an artificial one called Ac4c, which stops an enzyme called DPP-4 from destroying the drug within minutes. Second, they changed four building blocks in the middle of the chain (positions 16, 18, 20, 23) so the drug can also activate the GLP-1 receptor -- the target that controls appetite and blood sugar. Third, they attached a fatty acid tail at position 24 that sticks to albumin, a protein in your blood, creating a slow-release effect that makes one injection last a full week. Finally, they capped the tail end of the chain to prevent another set of enzymes from chewing it up.

A advanced: the Ac4c substitution and DPP-4 resistance term
Dipeptidyl peptidase-4 (DPP-4) cleaves native glucagon and GLP-1 between positions 2 and 3, destroying biological activity within minutes. Survodutide replaces the natural serine at position 2 with Ac4c (1-aminocyclobutane-1-carboxylic acid), an unnatural amino acid whose rigid four-membered cyclobutane ring creates a steric barrier too bulky for DPP-4's active site to accommodate. This is distinct from tirzepatide and retatrutide, which use Aib (alpha-aminoisobutyric acid) for the same purpose -- different steric solutions to the same enzymatic vulnerability. Without this single substitution, survodutide would have a half-life measured in minutes rather than days.
advanced: C18 fatty diacid acylation and the albumin depot
Lysine at position 24 is conjugated to an octadecanedioic acid (C18 fatty diacid) through a GGSGSG-gammaE linker that provides flexible spacing between the peptide backbone and the lipid tail. The fatty acid binds non-covalently to human serum albumin, achieving greater than 99% plasma protein binding. Only the tiny unbound fraction interacts with GCGR and GLP-1R on target cells. As free peptide is cleared, more dissociates from albumin to maintain equilibrium -- a slow-release depot within the vascular compartment. This extends the half-life from approximately 6 minutes (native glucagon) to approximately 6 days, a 1,440-fold increase that enables once-weekly subcutaneous dosing.
advanced: the SAR balancing act at positions 16-23
Grafting GLP-1R activity into a glucagon backbone is a structure-activity relationship (SAR) challenge because each substitution that improves GLP-1R binding risks disrupting native GCGR contacts. Zealand Pharma tested many analogs to find the minimum effective set: four amino acid swaps at positions 16, 18, 20, and 23, borrowed from GLP-1 and exendin-4 sequences. These create the molecular contacts needed for GLP-1R engagement (EC50 0.33 nM, about 4-fold less potent than native GLP-1) while preserving enough of the glucagon backbone to maintain GCGR activity (EC50 0.52 nM). More aggressive modification could have improved GLP-1R potency but at the cost of reduced GCGR engagement -- the exact tradeoff survodutide's design deliberately avoids.

modification map

the four categories of engineering that convert native glucagon into a long-acting dual agonist.

position 2: DPP-4 resistance
Ac4c replaces serine. blocks the primary enzymatic degradation pathway. without this substitution, survodutide would be destroyed within minutes of injection.
positions 16, 18, 20, 23: GLP-1R grafting
four amino acid swaps from GLP-1 and exendin-4 create the molecular contacts needed for GLP-1 receptor engagement. these convert a pure GCGR agonist into a dual agonist with EC50 of 0.33 nM at GLP-1R.
position 24: albumin binding
lysine-24 carries a C18 fatty diacid via a GGSGSG-gammaE linker. >99% plasma protein binding creates a slow-release depot, extending the half-life from ~6 minutes to ~6 days -- a 1,440-fold increase.
C-terminus: amidation
the terminal carboxyl group is converted to a carboxamide, blocking carboxypeptidase degradation. combined with the other modifications, survodutide is stabilized against all three major peptide degradation pathways.

backbone comparison

how survodutide's design philosophy differs from the other major incretin therapies.

semaglutide
GLP-1 backbone, 31 amino acids, C18 fatty diacid at position 26. pure GLP-1R mono-agonist. MW 4,113.58 Da, half-life ~7 days.
tirzepatide
GIP backbone, 39 amino acids, C20 fatty diacid at position 20. GLP-1/GIP dual agonist. MW 4,813.53 Da, half-life ~5 days.
survodutide
glucagon backbone, 29 amino acids, C18 fatty diacid at position 24. GLP-1/GCGR dual agonist. MW 4,231.63 Da, half-life ~6 days.
retatrutide
GIP backbone, 39 amino acids, C20 fatty diacid at position 17. GLP-1/GIP/GCGR triple agonist. half-life ~6 days.